Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

Generalized Epilepsy Clinical Trial

Official title:
An Open-label, Multicenter, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (Oral Tablets of 166, 250 or 500 mg b.i.d.), at Individualized Doses up to a Maximum of 4000 mg/Day (or 80 mg/kg/Day for Children and Adolescents Less Than 50 kg), in Children (≥ 4 Years Old), Adolescents and Adults Suffering From Primary Generalized Seizures

Status Completed

Clinical Trial Summary

An open-label, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV), in children (≥ 4 years old), adolescents and adults suffering from primary generalized seizures.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00150748
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 3
Start date	November 2001
Completion date	July 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04965571` - Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
Completed	`NCT01311440` - Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy	N/A
Terminated	`NCT03955432` - Long-term Cardiac Monitoring in Epilepsy	N/A
Completed	`NCT00150735` - Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy	Phase 3
Recruiting	`NCT03457961` - Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong
Withdrawn	`NCT03368469` - Transcranial Direct Current Stimulation (tDCS) in Children and Adolescents With Epilepsy and Depression	N/A
Completed	`NCT03590197` - Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy	Phase 4
Completed	`NCT00001325` - Metabolic Abnormalities in Children With Epilepsy	N/A